Documents show profit-seeking behind price hikes at Turing, Valeant

Go back to Documents show profit-seeking behind price hikes at Turing, Valeant

Did Price or Volume Drive Valeant Pharma (VRX) Growth?; Evercore ISI's Raffat Digs In

February 2, 2016 11:41 AM EST

After trading above $100 early, Valeant Pharma (NYSE: VRX) shares have been volatile over the past several minutes as the Democratic Members of Oversight Committee just posted a memo detailing impressions on Valeant's pricing strategy.

While the stock has clearly seen some volatility, Evercore ISI analyst Umer Raffat said from a stock perspective the hearing "isn't too important."

That said, Raffat gets to the crux of the matter - was growth driven by price increase or by volume... More

Valeant (VRX) Comments on Oversight Committee Release of Documents; Plans Discounts on Popular Drugs (WBA)

February 2, 2016 11:28 AM EST

Valeant Pharma (NYSE: VRX) provided a statement on Oversight Committee release of documents:

Before Valeant purchased Nitropress and Isuprel, it commissioned outside consultants to review the drugs pricing. Those consultants concluded that, given the significant... More

Cummings Releases Memos Detailing Internal Corporate Documents on Skyrocketing Drug Prices

February 2, 2016 11:20 AM EST

Today, Rep. Elijah E. Cummings, Ranking Member of the House Committee on Oversight and Government Reform, sent two supplemental memos to Democratic Committee Members in preparation for a hearing he requested on skyrocketing prescription drug prices this Thursday.

The memos summarize findings from more than 300,000 pages of new... More